Self-administered injectable contraceptives, which are progestin-only shots taken at home every three months, have been ...

JERUSALEM, Nov. 19, 2025 /PRNewswire/ -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

argenx SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart, at a 1000 mg dose, administered through a subcutaneous ...

Injections deliver liquid medications, fluids, or nutrients directly into a person’s body. Different types of injections include intravenous, intramuscular, subcutaneous, intraosseous, and intradermal ...

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

SAN FRANCISCO -- A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of plasma concentrations compared with twice-yearly subcutaneous ...

Introduction: Needle-free injection system (NFIS) is easy to operate and can decrease needle phobia. Besides, NFIS can increase the interaction of antigens in a more dispersed manner with immune cell ...

Most people know the feeling of getting a shot and having your arm feel sore for several days afterward. Some might even expect it as a side effect. The soreness happens when medications are injected ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...